These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35342138)

  • 61. Dynamics of the Immune Response in Hospitalized SARS-CoV-2-infected Cancer Patients.
    Aoki MN; Nardin JM; Huergo LF; Blanes L; Morales HMP; Fornazari B; Conzentino MS; Migliorini MEA; Zanette DL
    Cancer Invest; 2022 Oct; 40(9):750-759. PubMed ID: 35950647
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Low Positivity Rate of Anti-SARS-CoV-2 IgG in Unvaccinated Patients With Rheumatic Diseases Treated With Rituximab.
    García-Fernández A; Morán-Álvarez P; Bachiller-Corral J; Vázquez-Díaz M
    J Clin Rheumatol; 2022 Dec; 28(8):424-428. PubMed ID: 35696998
    [No Abstract]   [Full Text] [Related]  

  • 63. Hematological Abnormalities in COVID-19: A Narrative Review.
    Rahman A; Niloofa R; Jayarajah U; De Mel S; Abeysuriya V; Seneviratne SL
    Am J Trop Med Hyg; 2021 Feb; 104(4):1188-1201. PubMed ID: 33606667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Brain stem encephalitis is a rare complication of COVID-19.
    Shamier MC; Crijnen YS; Bogers S; IJpelaar JW; de Vries JM; van der Jagt M; Spoor JKH; von der Thüsen JH; Schreurs MWJ; GeurtsvanKessel CH; Titulaer MJ
    J Neuroimmunol; 2023 Jan; 374():578007. PubMed ID: 36481703
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
    Aumann S; Tsubary U; Nachmias B; Ben Yehuda D; Lavie D; Goldschmidt N; Vainstein V; Libster D; Saban R; Shaulov A; Israel S; Avni B; Grisariu S; Bdolah-Amram T; Gatt M; Zimran E
    Eur J Haematol; 2023 Jul; 111(1):135-145. PubMed ID: 37096337
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency.
    Hirsiger JR; Weigang S; Walz AC; Fuchs J; Daly ML; Eggimann S; Hausmann O; Schwemmle M; Kochs G; Panning M; Warnatz K; Recher M; Berger CT
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2452-2455.e3. PubMed ID: 35779780
    [No Abstract]   [Full Text] [Related]  

  • 67. Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy.
    Colaneri M; Pieri TC; Roda S; Ricciardi A; Gotti M; Ferrari J; Arcaini L; Rattotti S; Piralla A; Giardina F; Ferrari G; Sacchi P; Zuccaro V; Baldanti F; Bruno R
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556068
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What is the long-term clinical significance of anti-SARS-CoV-2-specific IgG?
    Alberca GGF; Alberca RW
    Influenza Other Respir Viruses; 2021 May; 15(3):413-414. PubMed ID: 33131215
    [No Abstract]   [Full Text] [Related]  

  • 69. [Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):359-364. PubMed ID: 35680591
    [No Abstract]   [Full Text] [Related]  

  • 70. Rapid Emergence and Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Gamma (P.1) Variant in Haiti.
    Tagliamonte MS; Mavian C; Zainabadi K; Cash MN; Lednicky JA; Magalis BR; Riva A; Deschamps MM; Liautaud B; Rouzier V; Fitzgerald DW; Pape JW; Morris JG; Salemi M
    Clin Infect Dis; 2022 Jun; 74(11):2057-2060. PubMed ID: 34471930
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Post-COVID-19 syndrome in patients with haematological disorders who have survived infection with severe acute respiratory syndrome coronavirus-2.
    Willan J; Hernandez L; Katz H; Gray N; Bienz N
    Br J Haematol; 2022 Apr; 197(2):e19-e23. PubMed ID: 34961926
    [No Abstract]   [Full Text] [Related]  

  • 72. Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan.
    Haraguchi M; Yamamoto H; Watanabe O; Sakoh T; Ishida K; Ogura S; Katoh-Morishima M; Taya Y; Nishida A; Kaji D; Takagi S; Yamamoto G; Uchida N; Araoka H
    Bone Marrow Transplant; 2023 Sep; 58(9):1051-1053. PubMed ID: 37330600
    [No Abstract]   [Full Text] [Related]  

  • 73. Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Transfus Clin Biol; 2023 Feb; 30(1):19. PubMed ID: 36116733
    [No Abstract]   [Full Text] [Related]  

  • 74. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review.
    Bonuomo V; Ferrarini I; Dell'Eva M; Sbisà E; Krampera M; Visco C
    World J Virol; 2021 Nov; 10(6):312-325. PubMed ID: 34909405
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study.
    Minakata D; Uchida T; Nakano A; Takase K; Tsukada N; Kosugi H; Kawata E; Nakane T; Takahashi H; Endo T; Nishiwaki S; Fujiwara H; Saito AM; Saito TI; Akashi K; Matsumura I; Mitani K
    Int J Hematol; 2024 Feb; 119(2):183-195. PubMed ID: 38172385
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Longitudinal changes of SARS-CoV-2 immunoglobulin G and immunoglobulin M in psychiatric disorders with coronavirus infection.
    Inuo E; Miyashita M; Yasui F; Matsumura K; Sakashita K; Hayashi E; Ono M; Sugii S; Kohara M; Saito M
    Psychiatry Clin Neurosci; 2023 Feb; 77(2):124-125. PubMed ID: 36449263
    [No Abstract]   [Full Text] [Related]  

  • 77. Possible contact transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in healthcare settings in Japan, 2020-2021.
    Kurosu H; Watanabe K; Kurosawa K; Nakashita M; Kasamatsu A; Nakamura H; Yamagishi T; Mitsuhashi Y; Yano K; Hachiya Y; Odani T; Amishima M; Nekomiya Y; Matsui T; Yamada M; Kamiyama K; Kikuchi T; Takadate K; Watanabe C; Furusawa Y; Kase K; Hyodo Y; Suzuki H; Matsunaga T; Hori H; Kanoh M; Miyake Y; Yamada M; Kobayashi Y; Sugai M; Suzuki M; Sunagawa T
    Infect Control Hosp Epidemiol; 2022 Sep; 43(9):1296-1298. PubMed ID: 34039453
    [No Abstract]   [Full Text] [Related]  

  • 78. SARS-CoV-2 Infection: Differences in Hematological Parameters Between Adults and Children.
    Liu L; She J; Bai Y; Liu W
    Int J Gen Med; 2021; 14():3035-3047. PubMed ID: 34234532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease.
    Ikeda D; Fukumoto A; Uesugi Y; Tabata R; Miura D; Narita K; Takeuchi M; Watari T; Otsuka Y; Matsue K
    Blood Cancer J; 2023 Sep; 13(1):133. PubMed ID: 37666820
    [No Abstract]   [Full Text] [Related]  

  • 80. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency.
    Kuster JK; Unlu S; Makin TA; Par-Young J; Simonov M; Shafi S; Balanda M; Randolph C; Steele R; Hsu FI; Price C; Kohli-Pamnani A; Borish L; Lawrence MG; Kang I; Shin JJ
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):633-636.e3. PubMed ID: 34929372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.